Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Shionogi & Co., Ltd. (4507:JPX), powered by AI.
Shionogi & Co., Ltd. is currently trading at ¥2,787. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Shionogi & Co., Ltd. on Alpha Lenz.
Shionogi & Co., Ltd.'s P/E ratio is 13.9.
“Shionogi & Co., Ltd. trades at a P/E of 13.9 (undervalued) with solid ROE of 13.1%. Operating margin of 35.7% indicates strong profitability.”
Ask for details →Shionogi & Co., Ltd. is a leading pharmaceutical company specializing in the research, development, and distribution of pharmaceutical products. Established in Japan in 1878, Shionogi focuses primarily on three therapeutic areas: infectious diseases, pain/CNS, and oncology. The company is known for its commitment to innovation in drug discovery, aiming to address unmet medical needs through advanced healthcare solutions. Notably, Shionogi has made significant contributions to the development of anti-infective medications, including antibiotics and antiviral treatments, positioning itself as a key player in the fight against global health challenges. In addition to pharmaceuticals, Shionogi expands its reach through ventures in healthcare services and bioinformatics. As a prominent entity in the pharmaceutical industry, Shionogi holds strategic partnerships with various global companies and research institutions, enhancing its impact on the international market. With a dedication to enhancing the quality of life, Shionogi & Co., Ltd. continues to play a crucial role in addressing critical health issues through its innovative solutions and robust product pipeline.
“Shionogi & Co., Ltd. trades at a P/E of 13.9 (undervalued) with solid ROE of 13.1%. Operating margin of 35.7% indicates strong profitability.”
Ask for details →Shionogi & Co., Ltd. (ticker: 4507) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 4,955 employees. Market cap is $2.4T.
The current price is 2,787 with a P/E ratio of 13.91x and P/B of 1.74x.
ROE is 13.12% and operating margin is 35.73%. Annual revenue is $438.3B.